Hims & Hers Health, Inc. (NYSE:HIMS) Shares Sold by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. trimmed its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 30.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,172,974 shares of the company’s stock after selling 523,901 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.54% of Hims & Hers Health worth $28,363,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of HIMS. Rakuten Securities Inc. purchased a new stake in shares of Hims & Hers Health in the 4th quarter worth about $114,000. Avantax Advisory Services Inc. raised its position in Hims & Hers Health by 113.3% during the fourth quarter. Avantax Advisory Services Inc. now owns 26,456 shares of the company’s stock worth $640,000 after acquiring an additional 14,053 shares during the last quarter. Jupiter Asset Management Ltd. purchased a new stake in shares of Hims & Hers Health in the fourth quarter valued at about $7,132,000. SPX Gestao de Recursos Ltda purchased a new stake in shares of Hims & Hers Health in the fourth quarter valued at about $1,814,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Hims & Hers Health by 16.6% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,450 shares of the company’s stock valued at $785,000 after purchasing an additional 4,620 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 268,932 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the completion of the sale, the insider now directly owns 169,803 shares in the company, valued at $4,712,033.25. The trade was a 61.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Michael Chi sold 17,303 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $48.14, for a total transaction of $832,966.42. Following the completion of the sale, the insider now directly owns 193,601 shares of the company’s stock, valued at $9,319,952.14. The trade was a 8.20 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 969,191 shares of company stock valued at $34,005,375. Company insiders own 17.71% of the company’s stock.

Hims & Hers Health Stock Performance

Hims & Hers Health stock opened at $34.00 on Thursday. Hims & Hers Health, Inc. has a 1 year low of $11.20 and a 1 year high of $72.98. The firm has a 50 day moving average price of $38.23 and a 200 day moving average price of $27.90. The company has a market cap of $7.55 billion, a price-to-earnings ratio of 77.27 and a beta of 1.37.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.02. The company had revenue of $481.14 million during the quarter, compared to analysts’ expectations of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on HIMS shares. Morgan Stanley downgraded Hims & Hers Health from an “overweight” rating to an “equal weight” rating and lifted their price objective for the stock from $42.00 to $60.00 in a research report on Tuesday, February 18th. Piper Sandler boosted their price target on Hims & Hers Health from $24.00 to $35.00 and gave the stock a “neutral” rating in a report on Tuesday, February 25th. Citigroup reaffirmed a “sell” rating and set a $27.00 price objective on shares of Hims & Hers Health in a research note on Thursday, March 6th. Canaccord Genuity Group boosted their target price on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Finally, TD Cowen restated a “buy” rating and issued a $28.00 target price on shares of Hims & Hers Health in a report on Wednesday, November 20th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, Hims & Hers Health presently has a consensus rating of “Hold” and an average target price of $37.23.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.